

Data Sheet

Product Name: Abciximab

Cat. No.: CS-0031162

CAS No.: 143653-53-6

Target: Integrin

Pathway: Cytoskeleton
Solubility: 10 mM in DMSO

Abciximab

BIOLOGICAL ACTIVITY:

Abciximab (C7E3), a chimeric mouse/human monoclonal antibody, is a **glycoprotein (GP) Ilb/Illa** inhibitor. Abciximab inhibits platelet aggregation and leucocyte adhesion by binding to the glycoprotein Ilb/Illa, vitronectin and Mac-1 receptors^[1]. *In Vitro:* Abciximab (C7E3) inhibits platelet aggregation induced by physiologic and pathologic agonists by binding to the platelet $\alpha_{\text{Ilb}}\beta_3$ integrin^[2]. Abciximab appears to have similar affinity for the $\alpha_{\text{Ilb}}\beta_3$ and $\alpha_{\text{V}}\beta_3$ integrins and redistributes between them^[2]. *In Vivo:* Abciximab (C7E3) (0.25 mg/kg/day; i.v.; 28 days) effectively prevents neointimal hyperplasia^[2].

References:

[1]. Ibbotson T, et al. Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation. Drugs. 2003;63(11):1121-63.

[2]. Wu CH, et al. Mechanisms involved in the inhibition of neointimal hyperplasia by abciximab in a rat model of balloon angioplasty. Thromb Res. 2001 Feb 1;101(3):127-38.

CAIndexNames:

Immunoglobulin G1Immunoglobulin G1, anti-(human integrin α IIb β 3) Fab fragment (human-mouse monoclonal c7E3 clone p7E3VHhC γ 1 γ 1-chain), disulfid e with human-mouse monoclonal c7E3 clone p7E3VkhC κ κ-chain, anti-(human integrin α IIb β 3) Fab fragment (human-mouse monoclonal c7E3 clone p7E3VkhC κ 1 γ 1-chain), disulfide with human-mouse monoclonal c7E3 clone p7E3VkhC κ 5-chain

SMILES:

[Abciximab]

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 610-426-3128 Fax: 888-484-5008 E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr., Suite Q., Monmouth Junction, NJ 08852, USA

Page 1 of 1 www.ChemScene.com